What side effects are associated with this type of intervention?

Common treatments for lung cancer, such as chemotherapy, targeted therapy, and immunotherapy, have various side effects. Chemotherapy often causes nausea, vomiting, hair loss, fatigue, and increased infection risk. Targeted therapies can lead to skin rashes, diarrhea, and liver issues. Immunotherapy may result in immune-related side effects like inflammation of the lungs, liver, or other organs, along with fatigue and skin reactions.

What prior FDA approvals exist?

The FDA has approved several treatments for lung cancer, particularly focusing on immunotherapy and targeted therapies. Notable approvals include pembrolizumab (Keytruda) for use in combination with chemotherapy for advanced non-small-cell lung cancer (NSCLC), which has shown significant improvements in overall survival and progression-free survival. Atezolizumab (Tecentriq) is another approved immunotherapy, often used in combination with chemotherapy for first-line treatment of metastatic non-squamous NSCLC. Additionally, targeted therapies like capmatinib for MET exon-14-skipping mutations and EGFR tyrosine kinase inhibitors for EGFR-mutated NSCLC have been approved, offering personalized treatment options. These advancements align with efforts to enhance lung cancer screening and early detection through innovative communication strategies.

What other types of research exist?

Promising, novel alternatives to LungTalk and Facebook-targeted Advertisement for increasing lung cancer screening uptake include the use of artificial intelligence (AI) for personalized communication, mobile health (mHealth) applications, telehealth services, community-based interventions, social media influencers, and virtual reality (VR) experiences.

← Back to Search

LungTalk for Increasing Lung Cancer Screening

N/A

Recruiting

Led By Lisa Carter-Bawa, PhD

Research Sponsored by Hackensack Meridian Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Individuals who currently smoke or quit smoking within the past 15 years

Be older than 18 years old

Must not have

Has ever been diagnosed with lung cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 6 months from baseline survey completion

Awards & highlights

No Placebo-Only Group

Summary

This trial uses a program called LungTalk and Facebook ads to encourage high-risk individuals to get screened for lung cancer. The goal is to increase awareness and motivate people to undergo screening. By targeting those at higher risk, the intervention aims to catch lung cancer early when it is more treatable.

Who is the study for?

The INSPIRE-Lung Study is for individuals who have a history of heavy smoking (at least 20 pack-years), including current smokers or those who quit within the last 15 years. It's not for people who've already had lung cancer screening, are being monitored for lung nodules, have been diagnosed with lung cancer, or have impaired decision-making.

What is being tested?

This study tests 'LungTalk', a communication intervention aimed at increasing lung cancer screening rates among high-risk groups using Facebook-targeted advertisements. It compares LungTalk to standard practices without tailored interventions.

What are the potential side effects?

Since this trial focuses on communication strategies rather than medical treatments, there are no direct side effects like you'd expect from drugs or surgeries. However, participants may experience emotional or psychological responses to the content.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a current smoker or quit smoking within the last 15 years.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 6 months from baseline survey completion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 6 months from baseline survey completion

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months from baseline survey completion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Effectiveness of LungTalk - Knowledge Assessment

Effectiveness of LungTalk - Occurrence of a Patient-Clinician Discussion

Effectiveness of LungTalk - Perceived Barriers

+7 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Tailored health communication intervention (LungTalk)Experimental Treatment1 Intervention

Participants will receive the tailored health intervention "LungTalk". LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool that is theoretically grounded in the Conceptual Model on Lung Cancer Screening Participation.

Group II: Non-tailored InterventionActive Control1 Intervention

Participants will receive non-tailored American Cancer Society (ACS) Lung Screening Informational Video as per standard of care. ACS Lung Screening Informational Video (ACS LSIV) is a non-tailored 5-minute video from the American Cancer Society about lung cancer screening designed for the lay individual.

0 / 2Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for lung cancer include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy kills rapidly dividing cells, including cancer cells, but also affects normal cells, leading to side effects. Targeted therapy uses drugs to specifically target genetic mutations or proteins involved in cancer cell growth and survival, offering a more precise treatment with potentially fewer side effects. Immunotherapy enhances the body's immune system to recognize and destroy cancer cells. These treatments are vital for lung cancer patients as they provide multiple strategies to control or eliminate cancer, improving survival rates and quality of life. Increasing lung cancer screening uptake through communication strategies like LungTalk and Facebook-targeted Advertisement is crucial for early detection and timely treatment, which can significantly improve patient outcomes.

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review.The management of non-small-cell lung cancer: a case history.